Table 3.
Strain (Phenotype) | Growth Reduction | Time (h) when Respective Growth Reduction Was Reached for the Following Concentrations (mg/L) of Antimicrobial Used | |||||||
---|---|---|---|---|---|---|---|---|---|
HY-133 | Oxacillin | ||||||||
0.25 | 0.5 | 1 | 4 | 0.25 | 0.5 | 1 | 4 | ||
OM299-1 (WT) | 90% | NR | NR | 1 | 1 | 8 | 4 | 2 | 2 |
99% | NR | NR | 1 | 1 | NR | 4 | 4 | 4 | |
99.9% | NR | NR | NR | 1 | NR | 8 | 8 | 8 | |
OM299-2 (SCV) | 90% | NR | 1 | 1 | 1 | 6 | 6 | 4 | 4 |
99% | NR | NR | 1 | 1 | 24 | 8 | 8 | 8 | |
99.9% | NR | NR | 1 | 1 | 24 | 24 | 24 | 24 | |
4652I (WT) | 90% | NR | 1 | 1 | 1 | NR | 4 | 4 | 2 |
99% | NR | NR | 1 | 1 | NR | 8 | 4 | 4 | |
99.9% | NR | NR | 1 | 1 | NR | 24 | 8 | 8 | |
4652II (SCV) | 90% | 1 | 1 | 1 | 1 | 4 | 4 | 4 | 2 |
99% | 1 | 1 | 1 | 1 | 8 | 4 | 4 | 4 | |
99.9% | NR | NR | 1 | 1 | NR | 6 | 6 | 4 | |
6850 (WT) | 90% | NR | 1 | 1 | 1 | NP | NP | NP | NP |
99% | NR | 1 | 1 | 1 | NP | NP | NP | NP | |
99.9% | NR | NR | 1 | 1 | NP | NP | NP | NP | |
JB1 (SCV) | 90% | 1 | 1 | 1 | 1 | NP | NP | NP | NP |
99% | NR | NR | 1 | 1 | NP | NP | NP | NP | |
99.9% | NR | NR | NR | 1 | NP | NP | NP | NP | |
IIb13 (SCV) | 90% | 1 | 1 | 1 | 1 | NP | NP | NP | NP |
99% | NR | 1 | 1 | 1 | NP | NP | NP | NP | |
99.9% | NR | NR | NR | 1 | NP | NP | NP | NP |
NR, not reached; NP, not performed. Data were extracted from time-kill curve measurements.